Quotables
"The radio craze will die out in time."
Thomas Edison ; 1922
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7794720 | Isolated plasma and method for hyperimmunisation and plasma collection The present invention relates to isolated canine animal plasma, a method for isolating canine animal plasma, plasma obtained form an immunised or hyperimmunised canine animal and treating a canine animal with the isolated canine animal plasma. The method includes th... | 09/14/2010 |
| 7311892 | Multidrug multiligand conjugates for targeted drug delivery Described is a multi drug multiligand conjugate for targeted drug delivery. The MDML conjugate contains a plurality of tripartite molecules linked to a central scaffold moiety, with each tripartite molecule comprising a targeting molecule, a therapeutic agent and a ... | 12/25/2007 |
| 7291334 | Antibodies to novel proteins in enteroaggregative (EAEC) useful for diagnosis and therapy of EAEC infections Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, an... | 11/06/2007 |
| 7285539 | Activation of HCV-specific T cells The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. HCV-specific T cells are activated using fusion proteins comprising HCV NS3, NS4, NS5a, and NS5b polypeptides... | 10/23/2007 |
| 7276240 | Antibodies to novel proteins in enteroaggregative (EAEC) useful for diagnosis and therapy of EAEC infections Novel proteins and their corresponding nucleotide sequences in enteroaggregative Escherichia coli (EAEC) are provided. In particular, Aap and the five gene cluster (aat) of the AA probe region of the pAA plasmid of EAEC 042 have been identified, sequenced, an... | 10/02/2007 |
| 7238351 | Immunogen adherence inhibitor directed to lactic acid producing organisms and method of making and using it The method of producing a microbial adherence inhibitor for administration to food animals to control the incidents of acidosis in food animals by preventing the adherence of colony-forming lactic acid producing bacteria in the rumen or intestinal tracts of the food... | 07/03/2007 |
| 7157562 | Bioprocess for the production of recombinant anti-botulinum toxin antibody A process for producing recombinant anti-botulinum toxin antibody comprising the steps of fermenting recombinant E. Coli cells in broth, concentrating the cells by removing the broth, crushing the concentrated cells, separating a permeate derived from the cru... | 01/02/2007 |
| 7147849 | Pharmaceutical formulation A pharmaceutical formulation containing at least one protein-containing substance and at least one substance selected from the group of compatible solutes. ... | 12/12/2006 |
| 7030101 | Compositions of β-glucans and specific antibodies Compositions and kits comprising combinations of β-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which β-glucan is administered to a subject... | 04/18/2006 |
| 7025963 | Vaccine against Gram-negative bacterial infections A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LP... | 04/11/2006 |
| 7018986 | Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are admin... | 03/28/2006 |
| 6995246 | Methods for removing suspended particles from soluble protein solutions The present invention provides soluble protein solutions, free of suspended particles in high yield. More particularly, the current invention provides a method for removing suspended particles from soluble protein solutions by filtering the soluble protein solution ... | 02/07/2006 |
| 6942861 | Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability The present invention describes the isolation and purification of histidine-tagged functional portions of intimin (his-tagged intimin or his-intimin), a protein associated with the ability of certain strains of pathogenic bacteria to adhere to epithelial cells. The ... | 09/13/2005 |
| 6790661 | System for detecting bacteria in blood, blood products, and fluids of tissues The invention provides methods for screening for the presence of a clinically relevant amount of bacteria in donor blood or a blood product from a donor mammal, particularly blood or a blood product that will be transferred from the donor mammal to a recipient mamma... | 09/14/2004 |
| 6749831 | Vaccine against lipopolysaccharide core Compare core LPS (lacking O-polysaccharide side chains) from Gram-negative bacteria are incorporated into a vaccine typically in liposomes. The complete core of E. coli K 12 is particularly useful. Upon administration to a mammal the vaccine stimulates synthe... | 06/15/2004 |
| 6737063 | FimH adhesin proteins and methods of use The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. Also provided are methods for vaccination of mammalian species, especially human patients, with variants of the E. coli... | 05/18/2004 |
| 6713059 | Antibodies raised against immunogenic conjugates of gram-negative bacterial autoinducer molecules The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals t... | 03/30/2004 |
| 6652857 | Methods for producing avian verotoxin antitoxin The present invention includes methods for generating neutralizing antitoxin directed against verotoxins. In preferred embodiments, the antitoxin directed against these toxins is produced in avian species using soluble recombinant verotoxin proteins. This... | 11/25/2003 |
| 6605272 | Methods of using zalpha11 ligand The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in ... | 08/12/2003 |
| 6355625 | Compositions of ଲ-glucans and specific IGIV Compositions and kits comprising combinations of ଲ-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which ଲ-glucan is admi... | 03/12/2002 |
| 6315999 | Pharmaceutical product for the treatment of sepsis An antibody to tumor necrosis factor- (anti-TNF) and an antibody to bacterial lipopolysaccharide (anti-LPS) used together in a neutropenic rat model of sepsis are shown to enhance survival of the rats relative to either antibody used alone. Pharmac... | 11/13/2001 |
| 6291649 | Anti-bodies binding adhesin-derived antigens An antigen which, as its major immunizing component, comprises a determinant of an adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunogenically active form, antibodies against whic... | 09/18/2001 |
| 6121296 | Transition-state inhibitors for nucleoside hydrolase and transferase reactions This invention is directed to transition-state analog compounds and to the use of said compounds as inhibitors of nucleoside hydrolase and transferase enzyme activity of parasites. This invention is further directed to the use of said compounds to treat i... | 09/19/2000 |
| 5914114 | Method of raising antibodies against E. coli of the family CS4-CFA/I A consensus poptide of 36 amino acids has been designed which acts as an immunogen raising antibodies against the proteins of all members of the E. coli family CS4-CFA/1. While the N-terminus of members of this family of organisms shows a high degree of i... | 06/22/1999 |
| 5807551 | Method to provide artificial passive immunity in birds The invention provides methods for inducing long-term passive immunity in birds, through administration of superconcentrated antibodies to hatching eggs or to post-hatch birds. The superconcentrated antibodies may originate from any source, including avia... | 09/15/1998 |
| 5780028 | Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition A pharmaceutical composition consisting, of nontoxic components wherein the nontoxic components comprise a core element comprising an antibody which binds to an antigen wherein the core element is a compressed tablet wherein compression forces used to pre... | 07/14/1998 |
| 5718899 | Method and compositions for direct concentrated delivery of passive immunity Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue at times of risk of infe... | 02/17/1998 |
| 5707627 | Methods and compositions for the direct concentrated delivery of passive immunity Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue at times of risk of infe... | 01/13/1998 |
| 5681565 | Methods and compositions for passive immunotherapy The direct, concentrated local delivery of antibodies, and pooled human immunoglobulins in particular, to tissue surfaces (e.g., wounds, burns, etc.), and biomaterial implant surfaces significantly decreases the rate of infection at those sites and enhanc... | 10/28/1997 |
| 5593679 | Poultry vaccine against E. coli air sac inflammation and septicaemia The present invention is concerned with vaccines effective in protecting poultry against E. coli septicaemia, which contain or can cause the production of fimbriae of the F11 type or an immunogenic section thereof, or antibodies against these.... | 01/14/1997 |
| 5585098 | Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants A method for lowering somatic cell count in the milk of a lactating ruminant is disclosed. IgY antibodies are first obtained from the egg of a hen which has been actively immunized against one or more mastitis-causing pathogenic organisms by injection wit... | 12/17/1996 |
| 5512282 | Monospecific polyclonal antibodies to shiga-like toxins Disclosed herein are high titer, monospecific, polyclonal antibodies to Shiga-like toxins. Also disclosed are methods for producing such antibodies, compositions containing them, and methods for the diagnosis, prevention, and treatment of diseases caused ... | 04/30/1996 |
| 5505945 | Method and compositions for the direct concentrated delivery of passive immunity Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue times of risk of infecti... | 04/09/1996 |
| 5468484 | Method of prevention of pseudomonas infection The invention described includes methods and compositions useful in preventing infection by Pseudomonas aeruginosa and related organisms. Diclosed is a peptide having the sequence corresponding to an antigenic site in the protein exoenzyme S which is anti... | 11/21/1995 |
| 5208024 | Vaccine against E. coli septicaemia in poultry The present invention is concerned with vaccines effective in protecting poultry against E. coli septicaemia, which contain or can cause the production of fimbriae of the F11 type or an immunogenic section thereof, or antibodies against these.... | 05/04/1993 |
| 5198213 | Method of disease treatment utilizing an immunologically whey fraction Whey derived from ordinary milk includes a bottom fraction including lactose and minerals, a middle fraction including lower molecular weight proteins, and a top fraction including higher molecular weight proteins. The top whey fraction includes a measura... | 03/30/1993 |
| 5080895 | Specific antibody-containing substance from eggs and method of production and use thereof A substance which contains a specific antibody or specific transfer factor-like component is produced from the yolks or albumens or both of eggs of a hen which has been immunized against a selected antigen such as a pathogenic bacteria. The substance is a... | 01/14/1992 |
| 5066491 | Method of disease treatment utilizing an immunologically active whey fraction Whey derived from ordinary milk includes a bottom fraction including lactose and minerals, a middle fraction including lower molecular weight proteins, and a top fraction including higher molecular weight proteins. The top whey fraction includes a measura... | 11/19/1991 |
| 5017372 | Method of producing antibody-fortified dry whey A method of producing a dry whey protein powder fortified with naturally occurring polyclonal antibody IgG to preselected infectious intestinal disease antigens, primarily diarrhea-causing enterotoxigenic Escherichia coli bacteria bearing colonization fac... | 05/21/1991 |
| 4971794 | Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili Antibodies are produced by hyperimmunizing a mammal, such as cow, with a vaccine derived from E. coli bacteria. The bacterial strains in the vaccine are selected on the basis of their virulence characteristics, especially adhesion factors (pili), associat... | 11/20/1990 |
